Current Treatment Options in Neurology

, Volume 4, Issue 6, pp 445–453

Atherosclerotic risk factors in patients with ischemic cerebrovascular disease

  • Brett L. Cucchiara
  • Scott E. Kasner
Article

Opinion statement

Aggressive treatment of atherosclerotic risk factors can substantially reduce stroke risk in patients with a history of stroke or transient ischemic attack. Data from several recent large clinical trials provide convincing evidence of benefit for a number of specific therapies directed at this population. The authors recommend treatment with ramipril alone or perindopril plus indapamide regardless of blood pressure, provided there is no contraindication. For patients already taking a different angiotensinconverting enzyme (ACE) inhibitor, the authors do not routinely switch agents. The authors recommend use of simvastatin 40 mg per day in patients with a total cholesterol level of 135 mg/dL or greater, provided no contraindication exists. The authors also recommend consideration of gemfibrozil in patients with isolated low highdensity lipoprotein levels. In patients with diabetes mellitus, tight glycemic control has not been shown to reduce macrovascular complications such as stroke, but does reduce microvascular complications. However, diabetics should receive especially aggressive treatment of other vascular risk factors. There is no role for postmenopausal hormone replacement therapy in prevention of stroke. Weight loss for overweight patients, regular exercise, and a diet rich in fruits, vegetables, cereals, and fish, as well as low in fat and cholesterol, should be a standard recommendation for this group of patients. Treatment with folic acid, B6, and B12 for patients with elevated homocysteine appears rational, though this is unproven. However, there is no benefit to vitamin E, vitamin C, or beta-carotene supplementation. Smokers should stop. For every 43 smokers who quit, one stroke is prevented. Moderate consumption of alcohol (one to two drinks a day) may be beneficial, but heavy alcohol use (more than five drinks a day) increases stroke risk.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Hankey GJ, Warlow CP: Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 1999, 354:1457–1463.PubMedCrossRefGoogle Scholar
  2. 2.
    Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB: Probability of stroke: a risk profile from the Framingham Study. Stroke 1991, 22:312–318.PubMedGoogle Scholar
  3. 3.
    Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044–1054.PubMedGoogle Scholar
  4. 4.
    Rodgers A, MacMahon S, Gamble G, et al.: Blood pressure and risk of stroke in patients with cerebrovascular disease: The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996, 313:147.PubMedGoogle Scholar
  5. 5.
    Vasan RS, Larson MG, Leip EP, et al.: Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001, 345:1291–1297.PubMedCrossRefGoogle Scholar
  6. 6.
    Psaty BM, Smith NL, Siscovick DS, et al.: Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review and meta-analysis. JAMA 1997, 277:739–745.PubMedCrossRefGoogle Scholar
  7. 7.
    Staessen JA, Wang JG, Thijs L: Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001, 358:1305–1315.PubMedCrossRefGoogle Scholar
  8. 8.
    Progress Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001, 358:1033–1041. A large randomized controlled trial of perinodpril and indapamide in a population of patients with cerebrovascular disease. See text for details of trial results.CrossRefGoogle Scholar
  9. 9.
    The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 342:145–153. A large randomized controlled trial of ramipril in patients with known vascular disease or a high-risk of vascular disease, including patients with cerebrovascular disease. See text for details of trial results.CrossRefGoogle Scholar
  10. 10.
    Bosch J, Yusuf S, Pogue J, et al.: Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002, 324:699.PubMedCrossRefGoogle Scholar
  11. 11.
    Cucchiara B, Kasner SE: Use of statins in CNS disorders. J Neurol Sci 2001, 187:81–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Suh I, Jee SH, Kim HC, et al.: Low serum cholesterol and haemorrhagic stroke in men: Korea Medical Insurance Corporation Study. Lancet 2001, 357:922–925. An extremely large prospective observational study that showed no relationship between low serum cholesterol and risk of either intracerebral or subarachnoid hemorrhage.PubMedCrossRefGoogle Scholar
  13. 13.
    Byington RP, Davis BR, Plehn JF, et al.: Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation 2001, 103:387–392. A prospectively defined pooled analysis of three large, randomized controlled trials of pravastatin that showed no increase in the risk of hemorrhagic stroke with pravastatin treatment.PubMedGoogle Scholar
  14. 14.
    Crouse JRI, Byington RP, Hoen HM, Furberg CD: Reductase inhibitor monotherapy and stroke prevention. Arch Intern Med 1997, 157:1305–1310.PubMedCrossRefGoogle Scholar
  15. 15.
    Blauw GJ, Lagaay AM, Smelt AHM, et al.: Stroke, statins, and cholesterol: a meta-analysis of randomized, placebo-controlled, double-blind trials with HMGCoA reductase inhibitors. Stroke 1997, 28:946–950.PubMedGoogle Scholar
  16. 16.
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:7–22. A large randomized controlled trial of simvastatin in patients with known vascular disease, including patients with cerebrovascular disease. See text for details of trial results.CrossRefGoogle Scholar
  17. 17.
    Sacco RL, Benson RT, Kargman DE, et al.: High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study. JAMA 2001, 285:2729–2735. A well-designed case control study in a diverse patient population documenting a relationship between HDL levels and stroke risk.PubMedCrossRefGoogle Scholar
  18. 18.
    Koren-Morag N, Tanne D, Graff E, Goldbourt U: Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease: the bezafibrate infarction prevention registry. Arch Intern Med 2002, 162:993–999.PubMedCrossRefGoogle Scholar
  19. 19.
    Lindenstrom E, Boysen G, Nyboe J: Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 1994, 309:11–15.PubMedGoogle Scholar
  20. 20.
    Rubins HB, Robins SJ, Collins D, et al.: The Veterans Affairs High-density Lipoprotein Cholesterol Intervention Trial Study Group: gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418.PubMedCrossRefGoogle Scholar
  21. 21.
    Bezafibrate Infarction Prevention Study Group: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21–27.Google Scholar
  22. 22.
    Rizos E, Mikhailidis DP: Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention? Cardiovasc Res 2001, 52:199–207.PubMedCrossRefGoogle Scholar
  23. 23.
    Tanne D, Koren-Morag N, Graff E, Goldbourt U: Blood lipids and first-ever ischemic stroke/transient ischemic attack in the Bezafibrate Infarction Prevention (BIP) Registry: high triglycerides constitute an independent risk factor. Circulation 2001, 104:2892–2897.PubMedGoogle Scholar
  24. 24.
    Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins, cardiovascular disease, and death: the Framingham study. Arch Intern Med 1981, 141:1128–1131.PubMedCrossRefGoogle Scholar
  25. 25.
    Jamrozik K, Broadhurst RJ, Forbes S, et al.: Predictors of death and vascular events in the elderly: the Perth Community Stroke Study. Stroke 2000, 31:863–868.PubMedGoogle Scholar
  26. 26.
    Folsom AR, Rasmussen ML, Chambless LE, et al.: Prospective associations of fasting insulin, body fat distribution, and diabetes with risk of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Diabetes Care 1999, 22:1077–1083.PubMedCrossRefGoogle Scholar
  27. 27.
    Kuusisto J, Mykkanen L, Pyorala K, Laakso M: Noninsulin-dependent diabetes and its metabolic control are important predictors of stroke in elderly subjects. Stroke 1994, 25:1157–1164.PubMedGoogle Scholar
  28. 28.
    UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:837–853.CrossRefGoogle Scholar
  29. 29.
    Viscoli CM, Brass LM, Kernan WN, et al.: A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 2001, 345:1243–1249.PubMedCrossRefGoogle Scholar
  30. 30.
    Writing Group for the Women’s Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002, 288:321–333. A pivotal, recently reported large randomized controlled trial showing increased risk of stroke in patients on hormone replacement therapy.CrossRefGoogle Scholar
  31. 31.
    Stamler J, Rose G, Stamler R, et al.: INTERSALT study findings: public health and medical care implications. Hypertension 1989, 14:570–577.PubMedGoogle Scholar
  32. 32.
    Bazzano LA, He J, Ogden LG, et al.: Dietary potassium intake and risk of stroke in US men and women: National Health and Nutrition Examination Survey I epidemiologic follow-up study. Stroke 2001, 32:1473–1480.PubMedGoogle Scholar
  33. 33.
    Ascherio A, Rimm EB, Hernan MA, et al.: Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998, 98:1198–1204.PubMedGoogle Scholar
  34. 34.
    Gillman MW, Cupples LA, Gagnon D, et al.: Protective effect of fruits and vegetables on development of stroke in men. JAMA 1995, 273:1113–1117.PubMedCrossRefGoogle Scholar
  35. 35.
    Iso H, Rexrode KM, Stampfer MJ, et al.: Intake of fish and omega-3 fatty acids and risk of stroke in women. JAMA 2001, 285:304–312.PubMedCrossRefGoogle Scholar
  36. 36.
    Jamrozik K, Broadhurst R, Anderson C, Stewart-Wynne E: The role of lifestyle factors in the etiology of stroke: a population-based case-control study in Perth, Western Australia. Stroke 1994, 25:51–59.PubMedGoogle Scholar
  37. 37.
    Krauss RM, Eckel RH, Howard B, et al.: AHA Dietary Guidelines Revision 2000: a statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Stroke 2000, 31:2751–2766.PubMedGoogle Scholar
  38. 38.
    Loria CM, Ingram DD, Feldman JJ, et al.: Serum folate and cardiovascular disease mortality among US men and women. Arch Intern Med 2000, 160:3258–3262.PubMedCrossRefGoogle Scholar
  39. 39.
    Rimm EB, Willett WC, Hu FB, et al.: Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998, 279:359–364.PubMedCrossRefGoogle Scholar
  40. 40.
    Bots ML, Launer LJ, Lindemans J, et al.: Homocysteine and short-term risk of myocardial infarction and stroke in the elderly: the Rotterdam Study. Arch Intern Med 1999, 159:38–44.PubMedCrossRefGoogle Scholar
  41. 41.
    Homocysteine Lowering Trialists’ Collaboration: Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998, 316:894–898.Google Scholar
  42. 42.
    Schnyder G, Roffi M, Pin R, et al.: Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001, 345:1593–1600.PubMedCrossRefGoogle Scholar
  43. 43.
    The Heart Outcomes Prevention Evaluation Study Investigators: Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000, 342:154–160.CrossRefGoogle Scholar
  44. 44.
    Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002, 360:23–33.CrossRefGoogle Scholar
  45. 45.
    Walker SP, Rimm EB, Ascherio A, et al.: Body size and fat distribution as predictors of stroke among US men. Am J Epidemiol 1996, 144:1143–1150.PubMedGoogle Scholar
  46. 46.
    Rexrode KM, Hennekens CH, Willett WC, et al.: A prospective study of body mass index, weight change, and risk of stroke in women. JAMA 1997, 277:1539–1545.PubMedCrossRefGoogle Scholar
  47. 47.
    Wolf PA, Clagett GP, Easton JD, et al.: Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 1999, 30:1991–1994.PubMedGoogle Scholar
  48. 48.
    Abbott RD, Rodriguez BL, Burchfiel CM, Curb JD: Physical activity in older middle-aged men and reduced risk of stroke: the Honolulu Heart Program. Am J Epidemiol 1994, 139:881–893.PubMedGoogle Scholar
  49. 49.
    Wannamethee G, Shaper AG: Physical activity and stroke in British middle aged men. BMJ 1992, 304:597–601.PubMedCrossRefGoogle Scholar
  50. 50.
    NIH Consensus Development Panel on Physical Activity and Cardiovascular Health: Physical activity and cardiovascular health. JAMA 1996, 276:241–246.CrossRefGoogle Scholar
  51. 51.
    Shinton R, Beevers G: Meta-analysis of relation between cigarette smoking and stroke. BMJ 1989, 298:789–794.PubMedGoogle Scholar
  52. 52.
    Wolf PA, D’Agostino RB, Kannel WB, et al.: Cigarette smoking as a risk factor for stroke: the Framingham study. JAMA 1988, 259:1025–1029.PubMedCrossRefGoogle Scholar
  53. 53.
    Goldberg RJ, Burchfiel CM, Reed DM, et al.: A prospective study of the health effects of alcohol consumption in middle-aged and elderly men: the Honolulu Heart Program. Circulation 1994, 89:651–659.PubMedGoogle Scholar
  54. 54.
    Sacco RL, Elkind M, Boden-Albala B, et al.: The protective effect of moderate alcohol consumption on ischemic stroke. JAMA 1999, 281:53–60.PubMedCrossRefGoogle Scholar
  55. 55.
    Rodgers H, Aitken PD, French JM, et al.: Alcohol and stroke: a case-control study of drinking habits past and present. Stroke 1993, 24:1473–1477.PubMedGoogle Scholar
  56. 56.
    Lonn EM, Yusuf S, Jha P, et al.: Emerging role of angiotensin converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994, 90:2056–2069.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Brett L. Cucchiara
    • 1
  • Scott E. Kasner
  1. 1.Department of NeurologyThe University of Pennsylvania School of MedicinePhiladelphiaUSA

Personalised recommendations